TY - JOUR
T1 - Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borne encephalitis virus
AU - Kuznetsova, Nadezhda
AU - Siniavin, Andrei
AU - Butenko, Alexander
AU - Larichev, Victor
AU - Kozlova, Alina
AU - Usachev, Evgeny
AU - Nikiforova, Maria
AU - Usacheva, Olga
AU - Shchetinin, Alexey
AU - Pochtovyi, Andrei
AU - Shidlovskaya, Elena
AU - Odintsova, Alina
AU - Belyaeva, Elizaveta
AU - Voskoboinikov, Aleksander
AU - Bessonova, Arina
AU - Vasilchenko, Lyudmila
AU - Karganova, Galina
AU - Zlobin, Vladimir
AU - Logunov, Denis
AU - Gushchin, Vladimir
AU - Gintsburg, Alexander
N1 - Publisher Copyright:
© 2023 Kuznetsova et al.
PY - 2023/5
Y1 - 2023/5
N2 - Tick-borne encephalitis virus (TBEV) is one of the most threatening pathogens which affects the human central nervous system (CNS). TBEV circulates widely in Northern Eurasia. According to ECDC, the number of TBE cases increase annually. There is no specific treatment for the TBEV infection, thus vaccination is the main preventive measure. Despite the existence of several inactivated vaccines currently being licensed, the development of new TBEV vaccines remains a leading priority in countries endemic to this pathogen. Here we report new recombinant virus made by infectious subgenomic amplicon (ISA) approach using TBEV and yellow fever virus vaccine strain (YF17DD-UN) as a genetic backbone. The recombinant virus is capable of effective replication in mammalian cells and induce TBEVneutralizing antibodies in mice. Unlike the original vector based on the yellow fever vaccine strain, chimeric virus became neuroinvasive in doses of 107-106 PFU and can be used as a model of flavivirus neuroinvasiveness, neurotropism and neurovirulence. These properties of hybrid structures are the main factors limiting their practical use as vaccines platforms.
AB - Tick-borne encephalitis virus (TBEV) is one of the most threatening pathogens which affects the human central nervous system (CNS). TBEV circulates widely in Northern Eurasia. According to ECDC, the number of TBE cases increase annually. There is no specific treatment for the TBEV infection, thus vaccination is the main preventive measure. Despite the existence of several inactivated vaccines currently being licensed, the development of new TBEV vaccines remains a leading priority in countries endemic to this pathogen. Here we report new recombinant virus made by infectious subgenomic amplicon (ISA) approach using TBEV and yellow fever virus vaccine strain (YF17DD-UN) as a genetic backbone. The recombinant virus is capable of effective replication in mammalian cells and induce TBEVneutralizing antibodies in mice. Unlike the original vector based on the yellow fever vaccine strain, chimeric virus became neuroinvasive in doses of 107-106 PFU and can be used as a model of flavivirus neuroinvasiveness, neurotropism and neurovirulence. These properties of hybrid structures are the main factors limiting their practical use as vaccines platforms.
UR - http://www.scopus.com/inward/record.url?scp=85158821936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85158821936&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0284823
DO - 10.1371/journal.pone.0284823
M3 - Article
C2 - 37163522
AN - SCOPUS:85158821936
SN - 1932-6203
VL - 18
JO - PloS one
JF - PloS one
IS - 5 May
M1 - e0284823
ER -